Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10223
Title: Streptococcal Serology in Acute Rheumatic Fever Patients: Findings From 2 High-income, High-burden Settings.
Authors: Jack, Susan
Moreland, Nicole J
Meagher, Jess
Fittock, Marea
Galloway, Yvonne
Ralph, Anna P
Affiliation: From the Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.. Institute of Environmental Science and Research, Wellington, New Zealand..
School of Medical Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand..
Royal Darwin Hospital..
Northern Territory Rheumatic Heart Disease Control Program..
Institute of Environmental Science and Research, Wellington, New Zealand..
Royal Darwin Hospital.. Global and Tropical Health, Menzies School of Health Research, Darwin, Northern Territory, Australia..
Issue Date: Jan-2019
Citation: The Pediatric infectious disease journal 2019-01; 38(1): e1-e6
Abstract: Globally, there is wide variation in streptococcal titer upper limits of normal (ULN) for antistreptolysin O (ASO) and anti-deoxyribonuclease B (ADB) used as an evidence of recent group A streptococcal infection to diagnose acute rheumatic fever (ARF). We audited ASO and ADB titers among individuals with ARF in New Zealand (NZ) and in Australia's Northern Territory. We summarized streptococcal titers by different ARF clinical manifestations, assessed application of locally recommended serology guidelines where NZ uses high ULN cut-offs and calculated the proportion of cases fulfilling alternative serologic diagnostic criteria. From January 2013 to December 2015, group A streptococcal serology results were available for 350 patients diagnosed with ARF in NZ and 182 patients in Northern Territory. Median peak streptococcal titers were similar in both settings. Among NZ cases, 267/350 (76.3%) met NZ serologic diagnostic criteria, whereas 329/350 (94.0%) met Australian criteria. By applying Australian ULN titer cut-off criteria to NZ cases, excluding chorea, ARF definite cases would increase by 17.6% representing 47 cases. ASO and ADB values were similar in these settings. Use of high ULN cut-offs potentially undercounts definite and probable ARF diagnoses. We recommend NZ and other high-burden settings to use globally accepted, age-specific, lower serologic cut-offs to avoid misclassification of ARF.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10223
DOI: 10.1097/INF.0000000000002190
Type: Journal Article
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.